Cerus Corp. (CERS) Given Consensus Rating of “Buy” by Analysts
Cerus Corp. (NASDAQ:CERS) has been assigned an average rating of “Buy” from the eight brokerages that are covering the firm. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $9.10.
A number of research analysts have weighed in on the company. Cantor Fitzgerald set a $9.00 target price on Cerus Corp. and gave the company a “buy” rating in a report on Sunday, November 6th. Robert W. Baird set a $10.00 target price on Cerus Corp. and gave the company a “buy” rating in a report on Saturday, August 6th. FBR & Co reissued a “buy” rating and set a $10.00 price objective on shares of Cerus Corp. in a report on Monday, November 7th. Zacks Investment Research raised Cerus Corp. from a “sell” rating to a “hold” rating in a report on Wednesday, November 2nd. Finally, BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of Cerus Corp. in a report on Thursday, October 27th.
Cerus Corp. (NASDAQ:CERS) opened at 5.76 on Thursday. Cerus Corp. has a one year low of $4.22 and a one year high of $7.64. The company’s market cap is $595.96 million. The company has a 50-day moving average of $5.47 and a 200-day moving average of $6.03.
Cerus Corp. (NASDAQ:CERS) last posted its earnings results on Thursday, November 3rd. The company reported ($0.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.03. The business earned $10.20 million during the quarter, compared to analyst estimates of $10.34 million. Cerus Corp. had a negative return on equity of 76.76% and a negative net margin of 174.76%. The company’s quarterly revenue was up 27.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) EPS. Equities research analysts expect that Cerus Corp. will post ($0.64) EPS for the current fiscal year.
In related news, CFO Kevin Dennis Green sold 17,150 shares of the business’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $6.80, for a total value of $116,620.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Institutional Trust Company N.A. increased its stake in Cerus Corp. by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,559,771 shares of the company’s stock worth $15,179,000 after buying an additional 15,881 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in Cerus Corp. by 116.6% in the second quarter. Janney Montgomery Scott LLC now owns 111,967 shares of the company’s stock worth $702,000 after buying an additional 60,267 shares during the last quarter. Kennedy Capital Management Inc. purchased a new stake in Cerus Corp. during the first quarter worth $5,390,000. Hood River Capital Management LLC increased its stake in Cerus Corp. by 188.7% in the second quarter. Hood River Capital Management LLC now owns 1,888,557 shares of the company’s stock worth $11,785,000 after buying an additional 1,234,296 shares during the last quarter. Finally, First Midwest Bank Trust Division increased its stake in Cerus Corp. by 36.2% in the second quarter. First Midwest Bank Trust Division now owns 415,292 shares of the company’s stock worth $2,591,000 after buying an additional 110,275 shares during the last quarter. Institutional investors own 67.69% of the company’s stock.
About Cerus Corp.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Stock Ratings for Cerus Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corp. and related stocks with our FREE daily email newsletter.